The estimated Net Worth of David L. Hava is at least $4.24 millier dollars as of 20 March 2017. David Hava owns over 2,263 units of Pulmatrix Inc stock worth over $4,243 and over the last 9 years David sold PULM stock worth over $0.
Sign up
David Hava PULM stock SEC Form 4 insiders trading
David has made over 1 trades of the Pulmatrix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently David exercised 2,263 units of PULM stock worth $5,001 on 20 March 2017.
The largest trade David's ever made was exercising 2,263 units of Pulmatrix Inc stock on 20 March 2017 worth over $5,001. On average, David trades about 453 units every 0 days since 2015. As of 20 March 2017 David still owns at least 2,263 units of Pulmatrix Inc stock.
You can see the complete history of David Hava stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's David Hava's mailing address?
David's mailing address filed with the SEC is C/O PULMATRIX, INC.,, 990 HAYDEN AVE, LEXINGTON, MA, 02421.
Insiders trading at Pulmatrix Inc
Over the last 9 years, insiders at Pulmatrix Inc have traded over $4,537,500 worth of Pulmatrix Inc stock and bought 290,998 units worth $2,002,066 . The most active insiders traders include Steven Gillis, Terrance Mcguire et Innovative Sciences, Inc. O.... On average, Pulmatrix Inc executives and independent directors trade stock every 92 days with the average trade being worth of $521,728. The most recent stock trade was executed by David L. Hava on 20 March 2017, trading 2,263 units of PULM stock currently worth $5,001.
What does Pulmatrix Inc do?
pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. the platform, called isperse (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. the isperse powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.
What does Pulmatrix Inc's logo look like?
Complete history of David Hava stock trades at Pulmatrix Inc
Pulmatrix Inc executives and stock owners
Pulmatrix Inc executives and other stock owners filed with the SEC include:
-
Teofilo Raad,
President, Chief Executive Officer, Director -
Teofilo David Raad MBA,
Pres, CEO & Director -
Teofilo David Raad,
Pres, CEO & Director -
Michelle S. Siegert,
VP of Fin. and Principal Financial & Accounting Officer -
Michelle Siegert,
Vice President - Finance -
Michael Higgins,
Independent Chairman of the Board -
Timothy McCarthy,
Investor Relations -
Amit Munshi,
Independent Director -
Mark Iwicki,
Independent Director -
Rick Batycky,
Independent Director -
Christopher Cabell,
Director -
Todd Bazemore,
Director -
Dr. Margaret M. Wasilewski M.D.,
Chief Medical Officer -
Peter Ludlum CMA, MBA,
Interim CFO and Principal Accounting & Financial Officer -
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD,
Founder & Member of Scientific Advisory Board -
David J. Maki J.D.,
Advisor -
Dr. Alexander M. Klibanov Ph.D.,
Founder -
Prof. David A. Edwards,
Founder & Member of Scientific Advisory Board -
Dr. Robert S. Langer Jr.,
Founder & Member of Scientific Advisory Board -
Steven Arch Venture Fund Vi...,
-
David L. Hava,
Chief Scientific Officer -
Matthew L Sherman,
Director -
William E. Duke,
Chief Financial Officer -
Robert W. Clarke,
Chief Executive Officer -
Steven Gillis,
Director -
Kurt Graves,
Director -
Terrance Mcguire,
Director -
Scott M Rocklage,
Director -
Richard P. Batycky,
Director -
Venture Fund Vii, L.P.Arch ...,
-
James M. Roach,
Chief Medical Officer -
Terrance Flint Jonathan A P...,
-
Innovative Sciences, Inc. O...,
10% owner -
David Maki,
Director -
Anand Varadan,
Director -
Margaret Wasilewski,
Chief Medical Officer